China Medical University Hospital

Shine-on Biomedical Co., Ltd.

Yeh Chen

Der-Yang Cho

Shao-Chih Chiu

Shi-Wei Huang

Chih-Ming Pan

Mei-Chih Chen

Yu-Chuan Lin

Yi-Wen Chen

Chao-Jung Chen

Kai-Wen Kan

Ming-You Shie

Jia-Xin Yu

Po-Ren Hsueh

Tien Ni

The present disclosure provides an anti-specific antibody and the nucleic acid encoding sequence thereof, and uses of the same. The anti-specific antibody of the present disclosure achieves the effect of treatinginfection and enhancing immune cells againstthrough various efficacy experiments.

Anti-specific antibody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 &#x3b5;.

Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Growing community of inventors

Taichung, Taiwan

Yeh Chen